Condensed Interim Financial Statements

Statement of Profit or Loss

€ in millions	Q2 2021[1]	Q2 2020[1]	6-mo. 2021	6-mo. 2020
Sales revenue	838.1	546.9	1,629.2	1,056.8
Cost of sales	–382.7	–262.5	–756.9	–508.2
Gross profit on sales	**455.4**	**284.4**	**872.3**	**548.6**
Selling and distribution costs	–142.2	–107.6	–271.2	–210.3
Research and development expenses	–34.2	–24.3	–66.4	–49.9
General administrative expenses	–42.0	–30.7	–79.0	–60.6
Other operating income and expenses	–6.7	–24.5	–20.5	–41.7
Earnings before interest and taxes (EBIT)	**230.3**	**97.3**	**435.2**	**186.1**
Financial income	4.2	–0.3	14.5	12.3
Financial expenses	–22.1	–20.4	–63.2	–32.6
Financial result	**–17.9**	**–20.7**	**–48.7**	**–20.3**
Profit before tax	**212.4**	**76.6**	**386.4**	**165.7**
Income taxes	–66.4	–25.6	–126.5	–49.7
Net profit for the period	**145.9**	**50.9**	**259.9**	**116.0**
Attributable to:				
Shareholders of Sartorius AG	108.1	33.9	189.8	79.8
Non-controlling interest	37.9	17.1	70.1	36.2
Earnings per ordinary share (€) (basic)	**1.58**	**0.50**	**2.77**	**1.16**
Earnings per preference share (€) (basic)	**1.58**	**0.50**	**2.78**	**1.17**
Earnings per ordinary share (€) (diluted)	**1.58**	**0.50**	**2.77**	**1.16**
Earnings per preference share (€) (diluted)	**1.58**	**0.50**	**2.78**	**1.17**

1 The 2nd quarter figures were not included in the auditors' review.

The previous year's figures have been restated due to finalization of the purchase price allocation for the acquisition of the Life Science business from Danaher.

Statement of Comprehensive Income

€ in millions	**Q2 2021[1]**	Q2 2020[1]	**6-mo. 2021**	6-mo. 2020
Net profit for the period	**145.9**	**50.9**	**259.9**	**116.0**
Cash flow hedges	–4.2	7.8	–15.1	5.4
of which effective portion of the change in fair value	1.1	6.8	–3.6	4.7
of which reclassified to profit or loss	–5.4	1.0	–11.5	0.8
Income tax on cash flow hedges	1.3	–2.2	4.6	–1.5
Net investment in a foreign operation	–6.3	–25.2	15.3	–16.1
Income tax on net investment in a foreign operation	1.7	7.1	–4.1	4.7
Currency translation differences	–10.0	–5.9	31.6	–13.0
Items that may be reclassified in the profit or loss statement, net of tax	**–17.6**	**–18.3**	**32.3**	**–20.5**
Items that will not be reclassified in the profit or loss statement, net of tax	**2.9**	**0.4**	**2.9**	**0.4**
Other comprehensive income after tax	**–14.7**	**–17.9**	**35.2**	**–20.1**
Total comprehensive income	**131.3**	**33.0**	**295.1**	**95.9**
Attributable to:				
Shareholders of Sartorius AG	94.8	16.6	221.2	62.7
Non-controlling interest	36.5	16.4	73.9	33.2

1 The 2nd quarter figures were not included in the auditors' review.

The previous year's figures have been restated due to finalization of the purchase price allocation for the acquisition of the Life Science business from Danaher.

Statement of Financial Positions

Assets	June 30, 2021 € in mn	Dec. 31, 2020 € in mn
Non-current assets		
Goodwill	1,386.8	1,369.0
Other intangible assets	1,044.7	1,061.5
Property, plant and equipment	1,067.4	971.5
Financial assets	52.4	34.1
Other assets	1.5	1.5
Deferred tax assets	45.2	45.0
	3,597.9	**3,482.8**
Current assets		
Inventories	690.7	558.6
Trade receivables	374.8	314.3
Other financial assets	23.2	40.3
Current tax assets	22.4	15.2
Other assets	81.0	78.8
Cash and cash equivalents	423.6	203.4
	1,615.6	**1,210.7**
Total assets	**5,213.5**	**4,693.5**

Equity and liabilities	June 30, 2021 € in mn	Dec. 31, 2020[1] € in mn
Equity		
Equity attributable to Sartorius AG shareholders	**1,220.1**	**1,047.6**
Issued capital	68.4	68.4
Capital reserves	42.6	42.0
Other reserves and retained earnings	1,109.0	937.2
Non-controlling interest	410.7	354.6
	1,630.8	**1,402.2**
Non-current liabilities		
Pension provisions	76.4	80.4
Other provisions	11.9	11.9
Loans and borrowings	1,678.3	1,826.3
Lease liabilities	73.4	65.5
Other financial liabilities	323.2	302.2
Deferred tax liabilities	127.8	133.9
	2,290.9	**2,420.2**
Current liabilities		
Provisions	50.1	29.5
Trade payables	430.9	330.7
Loans and borrowings	347.3	175.4
Lease liabilities	23.0	20.0
Employee benefits	133.3	96.3
Other financial liabilities	67.8	48.7
Current tax liabilities	134.8	87.7
Other liabilities	104.6	82.7
	1,291.8	871.1
Total equity and liabilities	**5,213.5**	**4,693.5**

The previous year's figures have been restated due to finalization of the purchase price allocations for WaterSep BioSeparations.

Statement of Cash Flows

€ in millions	**6-mo. 2021**	6-mo. 2020
Profit before tax	386.4	165.7
Financial result	48.7	20.3
Depreciation | amortization of intangible and tangible assets	109.2	79.9
Change in provisions	17.9	7.3
Change in receivables and other assets	–60.1	–12.9
Change in inventories	–123.0	–55.4
Change in liabilities (without loans and borrowings)	154.9	52.9
Income taxes paid	–94.3	–44.2
Other non-cash items	1.0	1.9
Cash flows from operating activities	**440.7**	**215.4**
Capital expenditures	–147.2	–89.6
Other payments	–12.6	–3.8
Cash flow from investing activities	**–159.9**	**–93.3**
Payments for acquisitions of consolidated subsidiaries and other business operations, net of cash acquired	–0.1	–756.1
Cash flow from investing activities, acquisitions and disposals	**–160.0**	**–849.5**
Interest received	3.9	4.7
Interest paid and other financial charges	–12.1	–12.2
Dividends paid to:		
Shareholders of Sartorius AG	–48.2	0.0
Non-controlling interest	–17.5	–0.8
Changes in non-controlling interest	0.0	–1.0
Loans repaid	–197.0	–209.1
Loans raised	210.0	988.2
Cash flow from financing activities	**–61.0**	**769.8**
Net increase | decrease in cash and cash equivalents	**219.7**	**135.7**
Cash and cash equivalents at the beginning of the period	203.4	54.4
Change in scope of consolidation	0.3	0.0
Net effect of currency translation on cash and cash equivalents	0.1	0.5
Cash and cash equivalents at the end of the period	**423.6**	**190.7**

The previous year's figures have been restated due to finalization of the purchase price allocation for the acquisition of the Life Science business from Danaher.

Statement of Changes in Equity

€ in millions	Issued capital	Capital reserves	Hedging reserves
Balance at January 1, 2020	**68.4**	**40.7**	**1.4**
Net profit for the period	0.0	0.0	0.0
Cash flow hedges	0.0	0.0	4.4
Remeasurements of the net defined benefit liability	0.0	0.0	0.0
Currency translation differences	0.0	0.0	0.0
Net investment in a foreign operation	0.0	0.0	0.0
Tax effects	0.0	0.0	–1.3
Other comprehensive income after tax	**0.0**	**0.0**	**3.1**
Total comprehensive income	**0.0**	**0.0**	**3.1**
Share-based payment	0.0	0.7	0.0
Dividends	0.0	0.0	0.0
Purchase price liability Israel	0.0	0.0	0.0
Change in scope of consolidation	0.0	0.0	0.0
Other changes in non-controlling interest	0.0	0.0	0.0
Other changes in equity	0.0	0.0	0.0
Balance at June 30, 2020	**68.4**	**41.4**	**4.5**
Balance at January 1, 2021	**68.4**	**42.0**	**8.3**
Net profit for the period	0.0	0.0	0.0
Cash flow hedges	0.0	0.0	–12.2
Remeasurements of the net defined benefit liability	0.0	0.0	0.0
Currency translation differences	0.0	0.0	0.0
Net investment in a foreign operation	0.0	0.0	0.0
Tax effects	0.0	0.0	3.6
Other comprehensive income after tax	**0.0**	**0.0**	**–8.5**
Total comprehensive income	**0.0**	**0.0**	**–8.5**
Share-based payment	0.0	0.7	0.0
Dividends	0.0	0.0	0.0
Other changes in non-controlling interest	0.0	0.0	0.0
Other changes in equity	0.0	0.0	0.0
Balance at June 30, 2021	**68.4**	**42.6**	**–0.2**

The previous year's figures have been restated due to finalization of the purchase price allocation for the acquisition of the Life Science business from Danaher.

Pension reserves	Earnings reserves and retained profits	Difference resulting from currency translation	**Equity attributable to Sartorius AG shareholders**	Non-controlling interest	**Total equity**
–26.0	**710.0**	**15.8**	**810.4**	**282.8**	**1,093.2**
0.0	79.8	0.0	79.8	36.2	116.0
0.0	0.0	0.0	4.4	1.0	5.4
0.4	0.0	0.0	0.4	0.1	0.5
0.0	0.0	–9.6	–9.6	–3.4	–13.0
0.0	–15.6	0.0	–15.6	–0.5	–16.1
–0.1	4.7	0.0	3.3	–0.2	3.1
0.3	**–10.9**	**–9.6**	**–17.1**	**–3.0**	**–20.1**
0.3	**68.9**	**–9.6**	**62.7**	**33.2**	**95.9**
0.0	0.0	0.0	0.7	0.0	0.7
0.0	–24.3	0.0	–24.3	–8.9	–33.1
0.0	0.0	0.0	0.0	0.0	0.0
0.0	0.0	0.0	0.0	0.0	0.0
0.0	–0.9	0.0	–0.9	–0.1	–1.0
0.0	0.3	0.0	0.3	0.0	0.3
–25.7	**754.0**	**6.2**	**848.8**	**307.1**	**1,155.9**
–30.2	**1,013.5**	**–54.3**	**1,047.6**	**354.6**	**1,402.2**
0.0	189.8	0.0	189.8	70.1	259.9
0.0	0.0	0.0	–12.2	–2.9	–15.1
3.5	0.0	0.0	3.5	0.6	4.2
0.0	0.0	26.3	26.3	5.4	31.6
0.0	15.3	0.0	15.3	0.0	15.3
–1.0	–4.1	0.0	–1.5	0.7	–0.8
2.5	**11.2**	**26.3**	**31.4**	**3.8**	**35.2**
2.5	**201.0**	**26.3**	**221.2**	**73.9**	**295.1**
0.0	0.0	0.0	0.7	0.0	0.7
0.0	–48.2	0.0	–48.2	–17.5	–65.8
0.0	0.3	0.0	0.3	–0.3	0.0
0.0	–1.4	0.0	–1.4	0.0	–1.4
–27.7	**1,165.0**	**–28.0**	**1,220.1**	**410.7**	**1,630.8**

The previous year's figures have been restated due to finalization of the purchase price allocation for the acquisition of the Life Science business from Danaher.

Segment Report

According to IFRS 8, Operating Segments, the identification of reportable operating segments is based on the "management approach"; i.e., the segments are defined analogously to the internal control and reporting structure of an entity. Accordingly, the divisions called Bioprocess Solutions and Lab Products & Services are to be considered operating segments.

"Underlying EBITDA" is the key performance indicator of the operating segments of the Sartorius Group. EBITDA corresponds to earnings before interest (financial result), taxes, depreciation and amortization. "Underlying EBITDA" means EBITDA adjusted for extraordinary items. In this connection, extraordinary items are expenses and income that are of an exceptional or a one-time nature and accordingly distort the sustainable profitability of a segment and, from the Group's perspective, have a material impact on the net worth, financial position and earnings of the Group.

Apart from that, the recognition and measurement methods for the reportable segments conform to the general Group accounting principles.

	Sales revenue		Underlying EBITDA	
€ in millions	**6-mo. 2021**	6-mo. 2020	**6-mo. 2021**	6-mo. 2020
Bioprocess Solutions	1,266.5	809.3	460.2	247.2
Lab Products & Services	362.7	247.5	95.1	46.4
Total	**1,629.2**	**1,056.8**	**555.3**	**293.5**
Reconciliation to the profit before tax				
Depreciation and amortization			–109.2	–78.8
Extraordinary items			–10.9	–28.7
Earnings before interest and taxes (EBIT)			**435.2**	**186.1**
Financial result			–48.7	–20.3
Profit before tax			**386.4**	**165.7**

The previous year's figures have been restated due to finalization of the purchase price allocation for the acquisition of the Life Science business from Danaher.

Disaggregation of Revenue

Geographical Information by Segment

Under IFRS 15, revenue recognized from contracts with customers are disaggregated into the categories of the "nature of products" as well as "geographical regions" and presented in the following table. The categorization by "nature of products" corresponds to the reportable segments as the identification of the reportable segments is based, in particular, on the different products sold. Regional disaggregation of revenue is according to the customer's location.

	6-mo. 2021			6-mo.2020		
€ in millions	**Group**	Bioprocess Solutions	Lab Products & Services	**Group**	Bioprocess Solutions	Lab Products & Services
Sales revenue	**1,629.2**	**1,266.5**	**362.7**	**1,056.8**	**809.3**	**247.5**
▪ EMEA	682.5	539.2	143.3	419.5	310.9	108.6
▪ Americas	519.0	405.2	113.9	373.1	304.8	68.3
▪ Asia | Pacific	427.6	322.1	105.5	264.2	193.7	70.5

Notes to the Condensed Interim Financial Statements

1. General Information

Sartorius AG is a listed joint stock corporation established according to German law and is the highest level parent company of the Sartorius Group. The corporation is recorded in the German Commercial Register of the District Court of Göttingen (HRB 1970) and is headquartered at Otto-Brenner-Str. 20 in Göttingen, Federal Republic of Germany.

The Sartorius Group is a leading international partner of life science research and the biopharmaceutical industry. With innovative laboratory instruments and consumables, the Group's Lab Products & Services Division (LPS) concentrates on serving the needs of laboratories performing research and quality control at pharma and biopharma companies and those of academic research institutes. The Bioprocess Solutions Division (BPS) with its broad product portfolio focusing on single-use solutions helps customers to manufacture biotech medications and vaccines safely and efficiently.

2. Significant Accounting Policies

The consolidated annual financial statements of Sartorius AG for the period ended December 31, 2020, were prepared in accordance with the accounting standards of the International Accounting Standards Board (IASB) – the International Financial Reporting Standards (IFRS) – as they are to be applied in the EU. In the present interim financial statements that were prepared in conformance with the requirements of IAS 34 "Interim financial reporting," basically the same accounting and measurement principles were applied on which the past consolidated financial statements of fiscal 2020 were based with the exception of those principles that were effective in 2021 for the first time.

Furthermore, all interpretations of the International Financial Reporting Standards Interpretations Committee (IFRS IC) to be applied effective June 30, 2021, were observed. An explanation of the individual accounting and measurement principles applied is given in the Notes to the Financial Statements of the Group for the year ended December 31, 2020. The Standards applied for the first time and the amended significant accounting policies are explained in Section 4 below.

A list of the companies included in the scope of consolidation for the Group financial statements is provided in our 2020 Annual Report. In the current fiscal year, the following entity was included for the first time in the consolidated financial statements of the Group:

- Sartorius South Africa (Pty) Ltd., Midrand / Gauteng, South Africa

The Group obtained control over Sartorius South Africa (Pty) Ltd. on January 1, 2019. This entity, which had not been consolidated in the past due to materiality considerations, has been consolidated effective January 1, 2021.

For calculation of income tax expenses, the provisions of IAS 34.30(c) were applied in the interim consolidated financial statements; i.e., the best estimate of the weighted average annual income tax rate expected for the full financial year was generally applied (30%). The consideration of the non-deductible expense in connection with the valuation of the earn-out liability leads to a nominal rate of 32.7%.

3. Use of Judgments and Estimates

In preparing these interim financial statements, management has made judgments, estimates and assumptions, based on the conditions and expectations as of the reporting date. Actual results may differ from these estimates, however. The significant judgments and estimates have remained the same as those applied to the consolidated financial statements for the year ended December 31, 2020. However, the general level of uncertainty that is inherent in accounting estimates and assumptions remains higher than usual as a result of the ongoing COVID-19 pandemic crisis.

In the first half of 2021, the Group achieved double-digit growth in sales revenue and order intake. The Group did not experience major difficulties on the supply side so that business continuity has been ensured. The biopharma industry that is of particular relevance for the Group is largely independent of the overall economic developments. This notion has been confirmed again in the interim period and is especially true for the BPS Division, a total solutions provider for the biopharma industry, which has continued to experience increased demand related to the manufacture of coronavirus vaccines and Covid-19 therapeutics. The LPS Division also recorded double-digit growth in sales revenue and order intake in the first half of 2021 to which higher demand for laboratory products and coronavirus tests contributed as well.

4. Accounting Rules Applied for the First Time in the Current Fiscal Year

Standards to Be Applied for the First Time in 2021
The Group initially applied the following new accounting rules for the reporting period:

- Amendments to IFRS 9, Financial Instruments, IAS 39, Financial Instruments: Recognition and Measurement, and IFRS 7, Financial Instruments: Disclosures, IFRS 4, Insurance Contracts, and IFRS 16, Leases, Interest Rate Benchmark Reform (Phase 2)

- Amendments to IFRS 4, Insurance Contracts, Deferral of Effective Date of IFRS 9

The application of the new rules did not have a material impact on the consolidated interim financial statements.

5. Business Combinations

Acquisition of WaterSep BioSeparations LLC in 2020
On December 9, 2020, the Group acquired 100% of the shares in the U.S.-based entity WaterSep BioSeparations LLC. The company employs around 15 people in Marlborough, Massachusetts, USA. WaterSep BioSeparations develops, manufactures and markets hollow-fiber membrane devices and pre-sterilized assemblies for upstream and downstream biopharmaceutical applications. This acquisition is complementary to the Group's current offering for cell and gene therapy applications, cell harvesting and various solutions for intensified bioprocessing and is being integrated in the Bioprocess Solutions Division.

Determination of the acquisition-date fair values of the assets acquired and liabilities assumed as well as the consideration transferred was completed in 2021. The following table presents preliminary and final valuations:

€ in millions	Preliminary purchase price allocation	**Final purchase price allocation**
Other intangible assets	0.0	8.1
Property, plant and equipment	0.2	0.6
Inventories	0.4	0.5
Trade receivables	0.4	0.4
Other assets	0.1	0.1
Cash and cash equivalents	0.1	0.1
Lease liabilities	0.0	–0.3
Other liabilities	–0.1	–0.1
Net assets acquired	**1.1**	**9.2**
Purchase price (cash at acquisition date)	22.5	22.5
Contingent consideration	4.9	0.7
Goodwill	**26.3**	**14.0**

The purchase price amounts to €23.2 million of which €22.5 million was paid in cash. The parties further agreed on an earn-out component which depends on the future sales revenue in the years of 2021 to 2023 and is due in 2024. Until this contingent consideration is settled, the agreement is classified as a financial liability and measured at fair value through profit or loss on each reporting date. The contingent consideration was measured at a fair value of €0.7 million at the acquisition date. On the reporting date of June 30, 2021, the fair value amounted to €0.7 million. The lower end of the bandwidth of possible outcomes of the contingent consideration is zero; the upper limit is $9 million.

Expenses of €0.7 million directly attributable to the acquisition were recognized as other expenses in profit or loss. The other intangible assets comprise technologies (€6.6 million) and customer relationships (€1.4 million). The resulting goodwill represents synergies, such as those arising from WaterSep BioSeparations' access to the Group's worldwide sales and distribution network, the completion of the product portfolio of the Bioprocess Solutions Division and intangible assets that are not recognized separately, e.g., the know-how of the skilled workforce. Goodwill is tax deductible.

Acquisition of BIA Separations in 2020

On November 2, 2020, the Group acquired 100% of the shares in the Slovenian purification specialist BIA Separations Podjetje za separacijske tehnologije d.o.o. ("BIA Separations") headquartered in Ajdovščina, Slovenia. Purchase price allocation has not yet been completed. Therefore, the presentation of the acquisition and the subsequent accounting in the first half of 2021 is based on the preliminary purchase price allocation described in the notes to the 2020 consolidated financial statements of the Group. Please refer to the consolidated financial statements of 2020 for a detailed description of the transaction.

The parties to the transaction agreed on three tranches of earn-out payments based on the sales performance of the acquired business over the next five fiscal years. Depending on the sales performance, the sellers are entitled to receive additional shares in Sartorius Stedim Biotech S.A. Until settlement, this additional contingent consideration agreement is classified as a financial liability and measured at fair value through profit or loss at each reporting date.

On the reporting date of June 30, 2021, the fair value of the contingent consideration liability was measured at €289.2 million (December 31, 2020: €253.9 million). This change mainly reflects the increase of the share price of Sartorius Stedim Biotech S.A. as starting point for estimating the future share price at the expected settlement dates since December 31, 2020. Furthermore, the discount rates applied to calculate the present value of the future obligation were adjusted to reflect the market rates on June 30, 2021. The difference of about €35.3 million between the valuation as of December 31, 2020, and that on the reporting date was recognized in the financial result. The lower end of the bandwidth of possible outcomes of the contingent consideration is zero, while the upper limit cannot be quantified due to the settlement in shares. The key input parameters for the valuation of the financial liability are the sales revenue expectations for the next five years as well as the share price of Sartorius Stedim Biotech S.A. on the respective valuation date. The valuation results are less sensitive to realistic changes of other valuation parameters, e.g. the discount rates applied. Assuming 10% higher (lower) sales revenues in each of the five years of the plan period would result in an increase of the liability to be reported on the reporting date by approximately €38 million (decrease by approximately €33 million). If the share price of Sartorius Stedim Biotech S.A. had been 10% higher (lower) at the reporting date, the liability would have been €29 million higher (€29 million lower). The actual future outcomes may differ from these sensitivities that are determined by changing only the respective key input parameter in isolation.

6. Financial Instruments

The following table presents the carrying amounts and fair values of the Group's financial instruments as of June 30, 2021, and December 31, 2020, according to IFRS 9.

€ in millions	Category acc. to IFRS 9	**Carrying amount June 30, 2021**	**Fair value June 30, 2021**	Carrying amount Dec. 31, 2020[1]	Fair value Dec. 31, 2020[1]
Investments in non-consolidated subsidiaries	n/a	32.3	32.3	15.2	15.2
Financial assets	Equity instruments at fair value through profit or loss	4.5	4.5	4.5	4.5
Financial assets	Debt instruments at fair value through profit or loss	12.4	12.4	11.5	11.5
Financial assets	Measured at amortized cost	3.3	3.3	3.0	3.0
Financial assets (non-current)		**52.4**	**52.4**	**34.1**	**34.1**
Amounts due from customers for contract work (contract assets)	n/a	6.5	6.5	6.2	6.2
Trade receivables	Measured at fair value through other comprehensive income	158.9	158.9	119.4	119.4
Trade receivables	Measured at amortized cost	209.3	209.3	188.7	188.7
Trade receivables		**374.8**	**374.8**	**314.3**	**314.3**
Receivables and other assets	Measured at amortized cost	21.5	21.5	26.9	26.9
Derivative financial instruments	Held for trading	0.1	0.1	0.0	0.0
Derivative financial instruments in hedge relationships[2]	n/a	1.5	1.5	13.4	13.4
Other financial assets (current)		**23.2**	**23.2**	**40.3**	**40.3**
Cash and cash equivalents	**Measured at amortized cost**	**423.6**	**423.6**	**203.4**	**203.4**

€ in millions	Category acc. to IFRS 9	**Carrying amount June 30, 2021**	**Fair value June 30, 2021**	Carrying amount Dec. 31, 2020[1]	Fair value Dec. 31, 2020[1]
Loans and borrowings	**Financial liabilities at cost**	**2,025.6**	**2,042.9**	**2,001.8**	**2,009.8**
Trade payables	Financial liabilities at cost	226.2	226.2	189.8	189.8
Trade payables | payments received for orders (contract liabilities)	n/a	204.7	204.7	140.9	140.9
Trade payables		**430.9**	**430.9**	**330.7**	**330.7**
Derivative financial instruments in hedge relationships[2]	n/a	2.7	2.7	0.0	0.0
Other financial liabilities	Financial liabilities at fair value through profit or loss	289.9	289.9	254.6	254.6
Other financial liabilities	Financial liabilities at cost	98.4	98.4	96.3	96.4
Other financial liabilities		**391.0**	**390.9**	**350.9**	**351.0**

1 Figures adjusted for finalization of purchase price allocation WaterSep BioSeparations LLC

2 The amounts include the non-designated part of the contracts which totals -€0.4mn in total. (December 31, 2020: -€1.0mn)

The fair values of the financial instruments were determined on the basis of the market information available on the reporting date and are to be allocated to one of the three levels of the fair value hierarchy in accordance with IFRS 13.

Level 1 financial instruments are measured on the basis of prices quoted on active markets for identical assets and liabilities. In Level 2, financial instruments are measured on the basis of input factors, which are derivable from observable market data or on the basis of market prices for similar instruments. Level 3 financial instruments are measured on the basis of input factors that cannot be derived from observable market data.

The derivatives in the form of forward contracts and options to be recognized at fair value on the reporting date were measured on the basis of their quoted exchange rates and market yield curves (Level 2).

The financial investments measured at fair value are measured on the basis of the most recent reliable indicators available as of the reporting date, e.g., on the basis of the most recent financing round or historical cost of acquisition. No material changes to the fair values were recognized on the reporting date.

The financial liabilities at fair value through profit or loss from the contingent consideration agreements in connection with the acquisitions of BIA Separations and WaterSep BioSeparations are determined using updated valuation parameters as of the reporting date and are to be allocated to Level 3. For further information and sensitivities, see Section 5.

The fair values to be disclosed for financial liabilities recognized at amortized cost, especially liabilities to banks and those related to note loans ("Schuldscheindarlehen") were measured on the basis of the market interest rate curve, taking the current indicative credit spreads into account (Level 2).

The fair values of the remaining financial assets and liabilities to be disclosed approximate the carrying amounts on account of their predominantly short-term maturity or unchanged cost of acquisition. The maximum credit loss risk is reflected by the carrying amounts of the financial assets recognized in the statement of financial position.

The Group recognizes transfers between the levels of the fair value hierarchies at the end of the reporting period during which a change occurs. In the current reporting period, there were no transfers between the levels.

7. Related Companies and Persons

The Group companies included in the consolidated financial statements carry out business activities and transactions in related party relationships as defined by IAS 24. In particular, this concerns transactions with non-consolidated subsidiaries and are generally concluded according to the customary market terms.

In the reporting period, sales revenue of €0.0 million (H1 2020: €0.9 million) was generated by sales to these companies; there were receivables from loans and borrowings as well as trade receivables, both totaling €0.9 million (H1 2020: €11.7 million). A long-term service contract exists with an affiliate for which expenses of €5.0 million (H1 2020: €5.4 million) were incurred in the reporting period.

For further details, also on related companies and persons, see page 216 in our 2020 Annual Report.

8. Other Disclosures

In the interim reporting period, no asset impairments were identified. Generally, asset impairment tests need to be performed annually for goodwill and other assets with indefinite useful lives.

In the reporting period, the Annual Shareholders' Meeting of Sartorius AG approved dividends totaling €48.2 million, of which €24.0 million are for ordinary shares and €24.3 million for preference shares. The dividend was paid in the first half of 2021.

The condensed consolidated financial statements of the Group were authorized for issue by the Executive Board on July 20, 2021. Independent, certified auditors performed an audit review of this consolidated six-month report. The figures of the individual second quarter in the statement of profit or loss, as well as the statement of comprehensive income, were not part of this review.

9. Material Events After the Reporting Date

On July 1, 2021, the Group acquired a majority stake in the reagent manufacturer CellGenix GmbH. The company that is based in Freiburg, Germany, and has a sales subsidiary near the biotechnology hub in Boston, Massachusetts, USA, produces and markets cell culture components, such as GMP-grade growth factors, cytokines and media for manufacturing cell and gene therapy products. Founded in 1994 at the University Medical Center of Freiburg, CellGenix currently employs some 70 people and generated sales of more than €20 million in 2020.

The purchase price for the acquired stake of 51% of CellGenix GmbH amounted to approx. €100 million (net) and was paid in cash. The parties further agreed on options according to which the acquisition of an additional 25% of the shares is planned in 2023 and that of the remaining 24% stake in 2026. In view of the short period between the acquisition and the preparation of the consolidated interim financial statements, no preliminary revaluation of the acquired net assets and goodwill is available. It is expected that the intangible assets to be recognized separately will primarily reflect technologies and customer relationships. The transaction has not been recognized in the interim consolidated financial statements as the entity will be consolidated as of the acquisition date.